SAB Biotherapeutics Inc

SAB Biotherapeutics reported second quarter 2026 financial results and provided business highlights, including an operational runway through 2028. The company ended the quarter with $208.0 million in cash, cash equivalents, and investment securities. Research and development expenses rose to $16.2 million from $7.0 million a year earlier, while general and administrative expenses increased to $7.2 million from $2.7 million. Net loss widened to $22.5 million from $10.1 million in the prior-year period. The registrational SAFEGUARD study of SAB-142 in Stage 3 new onset type 1 diabetes has activated over 60 clinical sites, with enrollment on track for completion in the fourth quarter of 2026 and topline data expected in the second half of 2027. Breakthrough T1D awarded a grant to the PRISE-hATG study of SAB-142 in patients 100 days to two years from diagnosis, providing non-dilutive funding for a registrational trial that could expand the potential future label. SAB BIO also began construction of a second farm facility in South Dakota to increase manufacturing capacity and establish a redundant Tc-Bovine herd for long-term commercial supply.

SAB Biotherapeutics and Breakthrough T1D announced that Breakthrough T1D has awarded a research grant to Dr. Michael J. Haller of the University of Florida to support a clinical assessment of SAB-142 in Stage 3 type 1 diabetes patients. The study will evaluate whether SAB-142 can preserve endogenous C-peptide and regulate immune responses in individuals with residual beta cell activity between 100 days and 2 years after diagnosis. SAB-142 is a human polyclonal immunotherapeutic antibody currently in Phase 2b clinical trials for autoimmune type 1 diabetes. Barclays analyst Eliana Merle recently initiated coverage of SAB Biotherapeutics with an Overweight rating and a $13 price target, citing the immunotherapy's potential as a disease-altering treatment and expecting Phase 2b data in the second half of 2027 as a key catalyst.

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on SAB Biotherapeutics with a $10 price target in a June 15, 2026 note. Bodnar said Sanofi's accelerated approval of Tzield in Stage 3 type 1 diabetes validates the use of C-peptide as a surrogate endpoint, reducing development risk for SAB-142's ongoing SAFEGUARD trial. She also cited differentiation from Tzield and rabbit ATG on safety and immunogenicity, minimal immune-related toxicities in early data, and support for a twice-yearly maintenance regimen as reasons behind the firm's positive risk-reward view. The call followed a June 24 initiation by Barclays with an Overweight rating and a $13 target, arguing that SAB's $300 million market capitalization fails to reflect the potential $4 billion market opportunity for SAB-142 in type 1 diabetes therapy.

Barclays analyst Eliana Merle initiated coverage of SAB Biotherapeutics Inc. with an Overweight rating and a $13 price target, implying more than 235% upside from current levels. Merle sees SAB-142 as a potential disease-altering treatment for type 1 diabetes, with Phase 2b data expected in the second half of 2027 as the key catalyst. She views the regulatory path as de-risked following the recent approval of Tzield and believes the anticipated $4 billion opportunity for SAB-142 is not reflected in the company's $300 million market capitalization. Earlier, on May 22, Citi initiated coverage with a Buy rating and an $11 target, citing the company's potential to redefine the type 1 diabetes treatment landscape.